BIOMX INC. Indemnification AgreementIndemnification Agreement • April 4th, 2024 • BiomX Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (this “Agreement”) is made as of, by and between BiomX Inc., a Delaware corporation (the “Company”), and _________________________ (“Indemnitee”).
FIRST AMENDMENT TO EXCLUSIVE LICENCE Between Adaptive Phage Therapeutics, Inc. And UNITED STATES OF AMERICA As Represented By THE SECRETARY OF THE NAVYBiomX Inc. • April 4th, 2024 • Biological products, (no disgnostic substances)
The parties agree to amend the licensing Agreement number NMR-17-10010. This First Amendment to the license shall be effective as of the date of the last signature below (“Amendment Effective Date”).
EXCLUSIVE LICENSE Between Adaptive Phage Therapeutics, Inc. And UNITED STATES OF AMERICA As Represented By THE SECRETARY OF THE NAVYWhereas Licensee • April 4th, 2024 • BiomX Inc. • Biological products, (no disgnostic substances)
This exclusive License (hereinafter called “LICENSE”) is made and entered into by and between the United States of America as represented by the Secretary of the Navy (hereinafter called “LICENSOR”) and
CUI BIOLOGICAL MATERIALS LICENSE AGREEMENTLicense Agreement • April 4th, 2024 • BiomX Inc. • Biological products, (no disgnostic substances)
This Agreement is entered into between the Walter Reed Army Institute of Research (WRAIR) (hereinafter “LICENSOR”) a subordinate Laboratory of United States Army Medical Research and Materiel Command (“USAMRDC”), located at 503 Robert Grant Avenue, Silver Spring, Maryland 20910 and Adaptive Phage Therapeutics (APT)), (hereinafter “LICENSEE”), a private corporation, having its principal place of business at 708 Quince Orchard Road, Suite 205, Gaithersburg, Maryland 20878.
LICENSE MODIFICATION 1License Modification 1 • April 4th, 2024 • BiomX Inc. • Biological products, (no disgnostic substances)
THIS modification to the Non-Exclusive License Agreement Control Number: “W8IXWH-”(“Modification 1”), effective upon the last signature date below, is made by and between: Walter Reed Armv Institute of Research (WRAIR) (hereinafter “LICENSOR”) a subordinate Laboratory of United States Army Medical Research and Materiel Command (“USAMRDC”), located at 503 Robert Grant Avenue, Silver Spring, Maryland 20910 and Adaptive Phage Therapeutics (APT)), (hereinafter “LICENSEE”), a private corporation, having its principal place of business at 708 Quince Orchard, Suite 205, Maryland 20878.
